Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04050527
Other study ID # F-FR-52120-255
Secondary ID 2018-004369-15
Status Completed
Phase
First received
Last updated
Start date December 19, 2019
Est. completion date July 29, 2022

Study information

Verified date August 2022
Source Ipsen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the protocol is to assess the longitudinal attainment of person-centered and function related goals of patients who receive AbobotulinumtoxinA (aboBoNT-A) injections for adult lower limb spasticity over a period of 16 months.


Recruitment information / eligibility

Status Completed
Enrollment 438
Est. completion date July 29, 2022
Est. primary completion date July 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult male and female subjects =18 years of age - Primary diagnosis with unilateral adult lower limb nonprogressive spasticity. - Subject able to take more than five steps with or without assistance. - Decision to treat the lower limb with aboBoNT-A by the care provider made prior to, and independently from, the decision to enroll the subject in the observational study as per country label. - Previously untreated with BoNT-A (i.e. naïve to BoNT-A), or previously treated with a BoNT-A (i.e. non-naïve to BoNT-A). For those who were previously treated with BoNTA, they should have responded to BoNT-A treatment and at least 12 weeks should have elapsed from prior injection. - Signed informed consent prior to participation in the study. Exclusion Criteria: - Prior history of nonresponsiveness to BoNT-A therapy - Previous treatment with BoNT-A of less than 12 weeks prior to enrolment in study. - Current participation in any other clinical study or have participated within the 12 weeks prior to the Inclusion visit (Visit 1) of this study. - Severe limitations in passive range of motion/contractures in the affected limb (MAS=4 in at least one of the joints in the lower limb). - Limb surgery or intrathecal baclofen therapy placement for spasticity within 3 months. - Nonambulatory subject. - Pregnant and lactating women. - Progressive neurological conditions or diagnosis of cerebral palsy.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Australia Princess Alexandra Hospital Ipswich
Australia Royal Prince Alfred Hospital Rozelle
Brazil Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP) - Neurology Ribeirão Preto
Brazil Hospital de Base de São José do Rio Preto at Centro Integrado de Pesquisa (CIP) - Neurology São José Do Rio Preto
Canada Glenrose Rehabilitation Hospital Edmonton
Canada River Valley Health - Stan Cassidy Foundation - Stan Cassidy Fredericton
Canada McGill University Health Center Montréal
France CHU - Hôpital Pellegrin - Neurologie Bordeau
France CHU RAYMOND POINCARE - Neurology Garches
France Centre Hospitalier Regional Universitaire (CHRU) de Lille - Hopital Pierre Swynghedauw - Neurology Lille
France Höpital Sainte-Marie - Neurology Paris
France Centre Hospitalier Universitaire De Reims - Hopital Maison B Reims
France Pole Saint Helier Rennes
Germany Neurologie und Psychosomatik am Wittenbergplatz Berlin
Germany Universitätsklinikum Erlangen Erlangen
Germany Medizinische Hochschule Hannover - Neurology Neurologische Poliklinik Hannover
Germany Universitätsklinikum/Neurologie Luebeck
Germany Neurologische Klinik und Poliklinik Würzburg
Italy Università Degli studi della Campania - Luigi Vanvitelli - Neurologica Napoli
Italy Istituto Scientifico di Riabilitazione di Veruno, Fondazione Novara
Italy PO Villa Sofia, AO Ospedali Riuniti Villa Sofia-Cervello Palermo
Italy AO S.Camillo-Forlanini Roma
Italy Universita degli Studi di Verona - Centro di Ricerca in Riabilitazione Neuromotoria e Cognitiva (CRRNC) - Neurology Verona
Poland SP ZOZ Szpital Uniwersytecki w Krakowie Kraków
Poland Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologii im.M.Kopernika w Lodzi Lódz
Poland Instytut Psychiatrii i Neurologii Warsaw
Poland Mazowiecki Szpital Brodnowski w Warszawie Sp. z o.o. Brodnowskie Centrum Kliniczne Poliklinika Brodnowskiego Centrum Klinicznego Warsaw
Poland Wojewódzki Szpital Specjalistyczny we Wroclawiu Wroclaw
Russian Federation Regional state budget health institution "City Hospital ? 5" Barnaul
Russian Federation FGBOU VO "Ural state medical university" Ekaterinburg
Russian Federation SAHI Interregional Clinical Diagnostic Center Kazan
Russian Federation National Medical Research Treatment and Rehabilitation Center of the Ministry of Health of Russia Moscow
Russian Federation Bekhterev National Research Medical Center for Psychiatry Saint Petersburg
Russian Federation Federal State Budgetary Institution "All-Russian Center for Emergency Medicine and Medical Radiology named after A.M. Nikiforov" of the EMERCOM of Russia Saint-Petersburg
Russian Federation Pavlov First Saint-Petersburg State Medical University - Neurology Saint-Petersburg
United States Good Shepherd Rehabilitation Hospital - Neurology Allentown Pennsylvania
United States Yeshiva University - Albert Einstein College of Medicine - Montefiore Medical Center (MMC) - Neurology Bronx New York
United States Dayton Center for Neurological Disorders Centerville Ohio
United States Riverhills Healthcare Cincinnati Ohio
United States OrthoNeuro Columbus Ohio
United States University of Texas Southwestern Dallas Texas
United States Rancho Los Amigos National Rehabilitation Center (RLANRC) - Neurology Downey California
United States MossRehab - Einstein Medical Center Elkins Park Pennsylvania
United States Neurology Center of NE,PC - Neurology Foxboro Massachusetts
United States Beaumont Hospital, Grosse Pointe - Neurology Grosse Pointe Michigan
United States Kansas City Bone and Joint Clinic, P.A. (KCBJ) - Overland Pa Leawood Kansas
United States Medical College of Wisconsin - Froedtert Hospital Milwaukee Wisconsin
United States Rehabilitation Associates - Neurology Paoli Pennsylvania
United States The University of Utah School of Medicine Salt Lake City Utah
United States MedStar National Rehabilitation Hospital Washington District of Columbia
United States Wake Forest University Baptist Medical Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Ipsen

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Canada,  France,  Germany,  Italy,  Poland,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subject centred Goal Attainment Scaling Leg T score (GASleg T) Mean individual GASleg T score. Goal attainment for each goal will be recorded clinically on a 5-point verbal rating scale (range -2 to +2) and goal scores combined to give an aggregated T score using a standard formula (GASleg T score). Range meaning is -2 = much less than expected and +2 = much more than expected.
The subject and/or caregiver to identify the main goal areas and establish agreed person centred and function related goals guided by GASleg (usually one primary and up to two secondary goals) at each visit. Goal attainment will be evaluated at the routine follow up visit.
Goals will be redefined and/or newly set at each injection visit or as per routine practice if further injections are not given. Goals will be SMART [Specific, measurable, attainable, relevant, and time-based]
16 months
Secondary Muscle tone Muscle tone will be evaluated using the Modified Ashworth Scale (MAS) /Tardieu Scale according to clinical practice. The MAS is a six point scale (with available scores of 0, 1, 1+, 2, 3 and 4) reporting changes in muscle tone during muscle flexion or extension. Tardieu scale quantifies muscle spasticity by assessing the response of the muscle to stretch applied at specified velocities. It can therefore broadly differentiate between the two key factors explaining resistance to passive stretch, namely contracture (non-neural factors) and spasticity (neural factors). 16 months
Secondary Severity of different aspects of impairment Severity of different aspects of impairment in subjects with neurological injury will be evaluated using the Lower Limb Spasticity adapted Neurological Impairment Scale. (LLS-NIS) Higher LLS-NIS scores indicate more severe impairment (LLS-NIS). Higher LLS-NIS scores indicate more severe impairment. 16 months
Secondary Total dose injected per cycle 16 months
Secondary Report muscles injected 16 months
Secondary Report dose per muscle 16 months
Secondary Assess correlations of subject centered goals Correlations of subject centred goals and related standardised rating scales will be assessed using GASleg and standardised outcome measures selected according to the goals for treatment. 16 months
Secondary Evolution of Quality of Life Assess the evolution of QoL at each visit based on the EQ-5D-5L and the QoL element of LegA. This is a descriptive scale that covers 5 dimensions: mobility, self-care, usual activities,pain/discomfort and anxiety/depression. the scale consist of 5 levels, where level one corresponds to "no problems" and level 5 corresponds to "extreme problem". 16 months